Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Otsuka And Lundbeck Begin To Reap Rewards Of Partnership

This article was originally published in The Pink Sheet Daily

Executive Summary

The Japanese company and its Danish partner garnered FDA approval for the long-acting injectable form of the blockbuster antipsychotic Abilify – the first approval of the five compounds the companies are partnered on.

You may also be interested in...



Lundbeck CEO Ulf Wiinberg On Partnering For Japan’s CNS Market: An Interview With PharmAsia News (Part 2 of 2)

Lundbeck is closely tied with Otsuka for CNS development, giving the company the freedom to explore more R&D programs.

Lundbeck CEO Ulf Wiinberg On Partnering For Japan’s CNS Market: An Interview With PharmAsia News (Part 1 of 2)

Lundbeck’s close ties with Otsuka for CNS development give it the freedom to explore more R&D programs.

Otsuka Searches For Value In Portfolio Through Patient Compliance Technology

Alliance with Lundbeck emphasizes search for innovation in all corners of CNS research.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS075372

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel